Market Performance - The North Exchange 50 Index increased by 1.58% as of January 16, 2026, compared to the previous week[5] - The average market capitalization of North Exchange A-shares is 3.069 billion yuan[14] - The average daily trading volume for North Exchange A-shares was approximately 40.191 billion yuan, up 53.80% from the previous week[5] Sector Analysis - High-end manufacturing and new materials have become the main market themes recently[1] - The North Exchange A-shares have a turnover rate of 7.89%, which is significantly higher than that of the Sci-Tech Innovation Board and the Shanghai Stock Exchange Main Board[5] Investment Recommendations - Focus on high-prosperity sectors and scarce leading companies driven by policy catalysts, such as commercial aerospace, intelligent manufacturing, and digital economy[5] - The PE ratios for North Exchange A-shares, ChiNext, Shanghai Main Board, Shenzhen Main Board, and Sci-Tech Innovation Board are 73.80, 77.49, 14.08, 43.29, and 248.68 respectively, indicating significant valuation differentiation[22] Regulatory News - The National Development and Reform Commission and other departments issued guidelines to standardize government investment fund operations, effective for five years[10] - The Ministry of Commerce imposed anti-dumping duties on imported polysilicon from the U.S. and South Korea, with rates ranging from 4.4% to 113.8%[11] Risks - Policy risks may affect market stability, with potential volatility if policies do not meet expectations[23] - Liquidity risks remain, as the North Exchange's overall liquidity is lower than that of the main boards[23]

Group 1 - The financing balance of the North Exchange is approximately one-third of that of the ChiNext, indicating lower investor sentiment and market activity [1][11] - The North Exchange's financing balance reached a historical high of 92.85 billion yuan as of January 14, 2026, with a financing balance of 92.84 billion yuan [11][12] - The North Exchange's financing balance as a percentage of market capitalization was 1.25% in 2025, significantly lower than the ChiNext (3.57%) and the Sci-Tech Innovation Board (2.97%) [15][18] Group 2 - The North Exchange 50 Index reported 1,548.33 points, with a P/E ratio of 64.92X, while the North Exchange specialized and new index reached 2,666.88 points with a P/E ratio of 83.81X [2][32] - The average P/E ratios for key sectors in the North Exchange are as follows: high-end equipment (42.38X), information technology (96.48X), new chemical materials (47.82X), consumer services (49.03X), and biomedicine (37.32X) [39][44] - The North Exchange has seen a significant increase in daily trading volume, with an average of 409.81 billion yuan, up 55.52% from the previous week [31][33] Group 3 - The report recommends focusing on high-performing stocks within the North Exchange 50 and technology growth companies, particularly those with strong new production capabilities and scarcity attributes [46] - Recent IPOs have shown strong performance, with the first new stock of 2026, Kema Materials, experiencing a first-day increase of 371.27% [2][24] - The report highlights the active trading of North Exchange 50 constituent stocks, which generally show higher activity levels in financing and margin trading compared to non-constituent stocks [19][20]

Market Overview - The medical beauty sector experienced a decline of 1.79% on January 16, with Huaxi Biological leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] Individual Stock Performance - Jinbo Biological (920982) closed at 235.00, with a slight increase of 0.38% and a trading volume of 6758.42 lots [1] - ST Meigu (000615) closed at 3.43, up 0.29% with a trading volume of 12.66 million [1] - Aimeike (300896) closed at 146.31, down 1.68% with a trading volume of 35,000 [1] - Huaxi Biological (688363) closed at 46.31, down 2.24% with a trading volume of 51,600 [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 112 million yuan from main funds, while retail investors contributed a net inflow of 73.41 million yuan [1] - The detailed capital flow for individual stocks shows: - ST Meigu had a main fund net outflow of 446,500 yuan and a retail net inflow of 198,200 yuan [2] - Jinbo Biological experienced a main fund net outflow of 7.88 million yuan and a retail net outflow of 223,700 yuan [2] - Huaxi Biological had a significant main fund net outflow of 46.59 million yuan, with retail investors contributing a net inflow of 27.27 million yuan [2] - Aimeike faced a main fund net outflow of 64.99 million yuan, while retail investors had a net inflow of 45.95 million yuan [2]

Core Viewpoint - Chuang'er Bio has terminated its IPO counseling due to unresolved shareholder equity freeze issues, marking a significant setback in its long and tumultuous journey towards public listing [1][5][10]. Company Overview - Founded in 2002, Chuang'er Bio specializes in the research, development, and production of active collagen biomedical materials, and is recognized as a high-tech enterprise in China [4]. - The company launched its core brand "Chuangfukang," which held an 8% market share in the Chinese patch-type medical skin repair dressing market in 2019, ranking second in the industry [1][16]. Financial Performance - In the first half of 2025, Chuang'er Bio reported a revenue of 214 million yuan, a year-on-year increase of 16.98%, but its net profit attributable to shareholders dropped significantly by 55.99% to 13.21 million yuan [4][12]. - The company's revenue structure shows that collagen products accounted for 87.83% of total revenue, indicating its reliance on this segment [4][13]. IPO Journey - Chuang'er Bio's IPO attempts have been fraught with challenges, including two failed attempts to list on the Sci-Tech Innovation Board and the Beijing Stock Exchange due to financial performance issues and shareholder equity freezes [10][14]. - The company’s second-largest shareholder, Ding Yumei, has had her shares frozen, which has been a critical factor in the termination of the IPO process [5][8]. Industry Context - The tightening of regulatory policies in the "medical device" sector has significantly impacted the growth of companies like Chuang'er Bio, which was once a leader in the collagen dressing market [16][17]. - Competitors such as Jinjian Bio and Fuhua have successfully entered the capital market and expanded their technological and market advantages, leaving Chuang'er Bio at a disadvantage [17][19]. Market Dynamics - The collagen product market is becoming increasingly competitive, with new entrants intensifying the pressure on established players like Chuang'er Bio [18]. - The shift towards restructured collagen products is becoming a market and technological trend, benefiting companies that adapt to these changes [19].

Macro Economic Group - In December, M2 growth was 8.5%, exceeding Wind's expectation of 7.9% and up from 8.0% in November. M1 growth was 3.8%, matching expectations but down from 4.9% in November, indicating a slowdown in money velocity [4] - The total social financing (TSF) in December grew by 8.3%, slightly above the expected 8.2% but down from 8.5% in November. The TSF increment was 2.21 trillion yuan, surpassing the expected 1.82 trillion yuan but down from 2.49 trillion yuan year-on-year [4] - Bank credit in December increased by 910 billion yuan, exceeding the expected 679.4 billion yuan and up from 390 billion yuan in the previous month. However, it was down 800 billion yuan year-on-year [5] Industry Comprehensive Group - Siyi Electric (002028.SZ) reported a revenue of 21.2 billion yuan for 2025, a 37.2% year-on-year increase, with Q4 revenue reaching 7.38 billion yuan, up 46.1%. The net profit attributable to shareholders was 3.16 billion yuan, a 54.4% increase, exceeding market expectations [12] - Guanghe Technology (001389.SZ) forecasted a net profit of 980 million to 1.02 billion yuan for 2025, a growth of 45% to 50.8%. The Q4 net profit was estimated at 280 million yuan, a 50.4% increase, driven by strong demand for server PCB boards [13] Advanced Manufacturing Group - The UK AR7 offshore wind auction resulted in 8.4GW of capacity, exceeding expectations and marking a historical high. This sets the stage for significant supply chain orders in the coming years, with a peak delivery expected between 2028 and 2030 [15] - The State Grid has confirmed a total investment of 4 trillion yuan for the 14th Five-Year Plan, a 40% increase from the previous plan, focusing on accelerating ultra-high voltage construction and enhancing supply chain capabilities [16] Consumer Group - The Financial Regulatory Bureau emphasized the need for financial support to boost consumption and investment, particularly in sectors like real estate, healthcare, and small businesses. This is expected to benefit consumer sectors such as automobiles and home appliances [18] - Juzhi Bio's second collagen medical device has been approved, enhancing the focus on the collagen market, which is gaining traction in aesthetic and skin repair applications [19] - Liufeng Group reported a same-store sales growth of 15% for Q4 2025, driven by increased customer flow and product pricing strategies, indicating strong growth momentum [19]

Group 1 - The medical beauty sector increased by 0.18% on January 14, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] - Major stocks in the medical beauty sector showed varied performance, with Ai Meike closing at 151.77, up 0.30%, and Jinbo Biological down 1.14% at 238.58 [1] Group 2 - The net inflow of main funds in the medical beauty sector was 5.91 million yuan, while retail funds saw a net inflow of 12.26 million yuan [1] - The main funds for Ai Meike had a net inflow of 17.77 million yuan, while retail funds had a net inflow of 4.15 million yuan [2] - Jinbo Biological experienced a significant net outflow of main funds at 43.53 million yuan, indicating a negative trend [2]

Core Viewpoint - The report from CITIC Securities indicates a gradual recovery in high-end consumption in China since Q3 2025, driven by the wealth effect from rising stock markets, with positive signs from international luxury brands and high-end retail properties [1] Group 1: Recovery Indicators - International luxury brands have shown signs of recovery since Q2 2025, with revenue growth returning in the Asia-Pacific region by Q3 2025 [2] - High-end retail properties in China began to recover at the end of 2024 and early 2025, with improved occupancy rates and sales, particularly in top luxury malls [2] - The global luxury market also entered a recovery phase starting Q3 2025 [2] Group 2: Investment Opportunities in High-End Consumption - The recovery of high-end consumption is influenced by factors such as the proportion of VIC (Very Important Customer) groups, the sequence of consumption based on wealth increase, the elasticity of supply, and consumption trends [3] - Categories with strong initial demand, driven by social status and identity needs, are expected to recover first, while categories with a high proportion of VIC customers and good supply conditions will show more sustained growth [3] - The fastest-growing segments in the luxury market from 2019 to 2025 include luxury cruises, private jets, high-end dining, personal luxury goods, luxury hotels, and high-end home goods [3] Group 3: Recommended Investment Targets - The report recommends focusing on luxury jewelry and leather goods, high-end domestic beauty products, and high-end outdoor sports [4] - Specific companies to watch include gold and jewelry brands like Lao Pu Gold and Chow Tai Fook, beauty brands like Mao Ge Ping, and sportswear brands like Anta Sports [4] - Other areas of interest include high-end commercial real estate, high-end residential real estate, gaming, private aviation, high-end tourism and dining, and premium liquor [4]

Group 1 - The medical beauty sector increased by 0.4% on January 12, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4165.29, up 1.09%, while the Shenzhen Component Index closed at 14366.91, up 1.75% [1] - The trading volume and turnover for Ai Meike were 44,900 shares and 6.76 billion yuan, respectively [1] Group 2 - The net outflow of main funds in the medical beauty sector was 50.50 million yuan, while retail funds saw a net inflow of 24.49 million yuan [1] - The detailed fund flow for individual stocks showed significant net outflows for *ST Meigu and Jinbo Biological, with net outflows of 7.42 million yuan and 39.56 million yuan, respectively [2] - Ai Meike experienced a net outflow of 34.20 million yuan from main funds, indicating a 5.06% decrease in net shareholding [2]

Core Viewpoint - The light industry and beauty care sector is expected to stabilize and improve by 2026, driven by domestic demand policies and steady export growth, despite facing certain pressures in the broader environment [2] Domestic Demand - The "14th Five-Year Plan" year is anticipated to see an increase in domestic demand policies, coupled with a growing consumer pursuit of high-quality living, which opens up significant growth opportunities for the industry [2][3] Export Potential - The cross-border e-commerce penetration rate has substantial room for improvement, and the improvement of international relations along with the demand boost from emerging markets will further expand the market, injecting momentum into the industry's overseas expansion [2][3] Company Insights - Companies with core technology and brand advantages are expected to seize opportunities, with cutting-edge technology enhancing product competitiveness and brand strength breaking the price-performance competition [2] - These companies are likely to benefit from domestic demand and explore overseas markets through global layouts, leading the growth in the trend of high-quality industry development [2] Investment Focus - **Beauty Sector**: Focus on high-end skincare and makeup brands with Eastern cultural characteristics such as Maogeping (01318) and Lin Qingxuan (02657), as well as companies like Marubi Biotechnology (603983.SH) showing marginal improvements [3] - **Home Furnishing**: Attention on leading companies with strong channel capabilities and multi-category layouts like Oppein Home Group (603833.SH) and Kuka Home (603816.SH), as well as Man Wah Holdings (01999) benefiting from the anticipated recovery in the US real estate market due to Federal Reserve rate cuts [3] - **Two-Wheel & Motorcycle**: The two-wheeler market is generally stable with a natural replacement cycle, and companies like Yadea Technology (01585), Aima Technology (603529.SH), and Ninebot (689009.SH) are under focus as market expectations are currently pessimistic [3] Light Industry Consumption - **Personal Care**: Companies with a big product strategy and all-channel expansion capabilities such as Baiya Co., Ltd. (003006.SZ) and Weigao Medical (300888.SZ) are noteworthy [4] - **Stationery**: Product and channel optimization are key for stationery companies adapting to current consumer trends, with attention on Morning Glory (603899.SH) and Qixin Group (002301.SZ) [4] Jewelry Sector - Focus on Laopu Gold (06181), which is expected to see performance growth due to continuous channel expansion and market breakthroughs [5] Export Companies - Companies with significant technical barriers and brand advantages in high-demand segments such as Haoyang Co., Ltd. (300833.SZ) and Yiyi Co., Ltd. (001206.SZ) are of interest [5]

Market Performance - The North Exchange 50 Index increased by 5.82% compared to the previous week, while the Shanghai and Shenzhen 300 Index rose by 2.79% and the ChiNext Index by 3.89%[30] - The average market capitalization of North Exchange A-shares reached 3.197 billion yuan, with a daily average trading volume of approximately 26.13 billion yuan, up 34.57% from the previous week[5] Investment Recommendations - Focus on sectors with high industry prosperity and scarcity, particularly commercial aerospace, robotics, low-altitude economy, energy storage, solid-state batteries, and liquid cooling[40] - The PE ratios for North Exchange A-shares, ChiNext, Shanghai Main Board, Shenzhen Main Board, and Sci-Tech Innovation Board are 48.40, 45.54, 12.69, 24.07, and 78.26 respectively as of January 9, 2026[40] Economic Indicators - The Consumer Price Index (CPI) rose by 0.8% year-on-year in December 2025, marking the highest increase since March 2023[22] - The Producer Price Index (PPI) increased by 0.2% month-on-month in December 2025, but decreased by 1.9% year-on-year[22] Regulatory Developments - The People's Bank of China is expected to implement a prudent monetary policy, emphasizing the need for financial support for economic stability and growth in 2026[11] - The China Securities Regulatory Commission is intensifying efforts to combat financial fraud in the capital market, with 159 cases of financial fraud handled in 2024[18] Industry News - China applied for frequency resources for over 200,000 satellites in December 2025, indicating a significant expansion in the commercial aerospace sector[29] - The United Nations projects global economic growth at 2.7% for 2026, slightly lower than the 2.8% estimated for 2025, amid ongoing macroeconomic uncertainties[26]